company background image
6955 logo

Shandong Boan Biotechnology SEHK:6955 Stock Report

Last Price

HK$9.01

Market Cap

HK$4.8b

7D

-3.4%

1Y

-43.1%

Updated

12 Dec, 2024

Data

Company Financials +

Shandong Boan Biotechnology Co., Ltd.

SEHK:6955 Stock Report

Market Cap: HK$4.8b

6955 Stock Overview

Develops, manufactures, and commercializes biologics in Mainland China and internationally. More details

6955 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance2/6
Financial Health3/6
Dividends0/6

Shandong Boan Biotechnology Co., Ltd. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Shandong Boan Biotechnology
Historical stock prices
Current Share PriceHK$9.01
52 Week HighHK$16.12
52 Week LowHK$7.51
Beta0
1 Month Change2.27%
3 Month Change-1.31%
1 Year Change-43.12%
3 Year Changen/a
5 Year Changen/a
Change since IPO-54.49%

Recent News & Updates

Recent updates

Investor Optimism Abounds Shandong Boan Biotechnology Co., Ltd. (HKG:6955) But Growth Is Lacking

Mar 26
Investor Optimism Abounds Shandong Boan Biotechnology Co., Ltd. (HKG:6955) But Growth Is Lacking

Shareholder Returns

6955HK BiotechsHK Market
7D-3.4%1.4%2.1%
1Y-43.1%-1.9%21.7%

Return vs Industry: 6955 underperformed the Hong Kong Biotechs industry which returned -1.9% over the past year.

Return vs Market: 6955 underperformed the Hong Kong Market which returned 21.7% over the past year.

Price Volatility

Is 6955's price volatile compared to industry and market?
6955 volatility
6955 Average Weekly Movement5.8%
Biotechs Industry Average Movement10.8%
Market Average Movement9.0%
10% most volatile stocks in HK Market18.9%
10% least volatile stocks in HK Market4.1%

Stable Share Price: 6955 has not had significant price volatility in the past 3 months compared to the Hong Kong market.

Volatility Over Time: 6955's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2013777Hua Jiangwww.boan-bio.com

Shandong Boan Biotechnology Co., Ltd. develops, manufactures, and commercializes biologics in Mainland China and internationally. Its commercialized products include Boyounuo (BA1101) bevacizumab injection for the treatment of metastatic or recurrent non-small cell lung cancer (NSCLC), recurrent glioblastoma, epithelial ovarian, fallopian tube or primary peritoneal cancer, and cervical cancer; and Boyoubei BA6101, a human immunoglobulin G2 monoclonal antibody for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The company develops BA1102 denosumab injection to treat patients with skeletal-related events caused by multiple myeloma and bone metastases from solid tumors, as well as giant cell tumour of bone; BA5101 dulaglutide injection indicated for glycemic control in adults with type-2 diabetes; and BA9101 aflibercept intravitreous injection to treat neovascular wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinopathy of prematurity.

Shandong Boan Biotechnology Co., Ltd. Fundamentals Summary

How do Shandong Boan Biotechnology's earnings and revenue compare to its market cap?
6955 fundamental statistics
Market capHK$4.83b
Earnings (TTM)HK$66.14m
Revenue (TTM)HK$770.25m

73.0x

P/E Ratio

6.3x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6955 income statement (TTM)
RevenueCN¥719.84m
Cost of RevenueCN¥186.46m
Gross ProfitCN¥533.38m
Other ExpensesCN¥471.57m
EarningsCN¥61.81m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.12
Gross Margin74.10%
Net Profit Margin8.59%
Debt/Equity Ratio47.0%

How did 6955 perform over the long term?

See historical performance and comparison